Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced...

G Mountzios, J Naidoo, C Wang, BC Creelan… - American Society of …, 2024 - ascopubs.org

Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of
patients with advanced non–small cell lung cancer without driver genetic alterations. Most of …

Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer

J Shen, L Chen, Y Song, S Chen, W Guo, Y Li - AAPS Open, 2024 - Springer

Since the oncogenic rearranged during transfection (RET) gene fusion was discovered in
non-small cell lung cancer (NSCLC) in 2012, multiple-targeted kinase inhibitors (MKIs) …

Assurance methods for designing a clinical trial with a delayed treatment effect

JA Salsbury, JE Oakley, SA Julious… - Statistics in …, 2024 - Wiley Online Library

An assurance calculation is a Bayesian alternative to a power calculation. One may be
performed to aid the planning of a clinical trial, specifically setting the sample size or to …

Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer

Y Cheng, Z Ye, Y Xie, X Du, S Song, X Ding… - Clinical and …, 2024 - Springer

Purpose To investigate the potential clinical importance of continuing immunotherapy
beyond progression in patients with advanced non-small-cell lung cancer (aNSCLC) …

[HTML][HTML] Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

A Alhadeethi, SA Awwad, M Abed, AM Amin… - Cureus, 2024 - ncbi.nlm.nih.gov

Lung cancer remains a major global health challenge, contributing to substantial morbidity
and mortality rates. Nintedanib, a tyrosine kinase inhibitor, has demonstrated potential as a …